Compare WEX & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEX | CRSP |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.6B |
| IPO Year | 2005 | 2016 |
| Metric | WEX | CRSP |
|---|---|---|
| Price | $151.72 | $57.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 19 |
| Target Price | ★ $172.92 | $71.50 |
| AVG Volume (30 Days) | 445.6K | ★ 2.5M |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.64 | N/A |
| Revenue | ★ $2,624,500,000.00 | $38,337,000.00 |
| Revenue This Year | $1.74 | N/A |
| Revenue Next Year | $4.34 | $723.84 |
| P/E Ratio | $20.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $110.45 | $30.04 |
| 52 Week High | $188.70 | $78.48 |
| Indicator | WEX | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 55.84 | 53.77 |
| Support Level | $142.86 | $51.16 |
| Resistance Level | $155.14 | $59.77 |
| Average True Range (ATR) | 4.56 | 3.11 |
| MACD | 1.46 | 1.10 |
| Stochastic Oscillator | 83.04 | 83.07 |
WEX Inc is a provider of corporate payment solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. The company's prime end market is the United States of America.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.